Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34+ cells

Experimental Hematology

Volumn 28, Issue 4, 2000, Pages 460-470

  Scheding, Stefan ^a   Meister, Bernhard ^a   Bühring, Hans Jörg ^a   Baum, Charles M ^b   Mc Kearn, John P ^b   Bock, Thomas ^a   Kanz, Lothar ^a   Brugger, Wolfram ^a  

^a Department of Internal Medicine II Oncology Hematology   (Germany)

^b MONSANTO COMPANY   (United States)

Author keywords

CD34+; Ex vivo expansion; Granulopoietic postprogenitor cells; Hematopoietic progenitor cells; High dose chemotherapy; Peripheral blood progenitor cells; Transplantation

Indexed keywords

CD11B ANTIGEN; CD16 ANTIGEN; CD34 ANTIGEN; DANIPLESTIM; FLT3 LIGAND; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; FLOW CYTOMETRY; GRANULOCYTE PRECURSOR; HUMAN; HUMAN CELL; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ANTIGENS, CD34; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; CULTURE MEDIA, SERUM-FREE; ERYTHROPOIETIN; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GRANULOCYTES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-3; INTERLEUKIN-6; MEMBRANE PROTEINS; PEPTIDES; STEM CELL FACTOR;

EID: 0034049233     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00133-8     Document Type: Article

References (39)

1. To L.B., Roberts M.M., Haylock D.N., Dyson P.G., Branford A.L., Thorp D., Ho J.Q., Dart G.W., Horvath N., Davy M.L.et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 9:1992;277.
2. Schmitz N., Linch D.C., Dreger P., Goldstone A.H., Boogaerts M.A., Ferrant A., Demuynck H.M., Link H., Zander A., Barge A. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 347:1996;353.
3. Scheding S., Brugger W., Kanz L. Peripheral blood progenitor cell transplantation. Ganser A., Hoelzer D. Cytokines in the treatment of hematopoietic failure. 1998;Marcel Dekker Inc, New York. 51p.
4. Scheding S., Brugger W., Kanz L. Autologous stem cell transplantation and manipulation. Degos L., Linch D., Löwenberg B. Textbook of malignant haematology. 1999;Martin Dunitz Ltd, London. 383p.
5. Kanz L., Brugger W. Mobilization and ex vivo manipulation of peripheral blood progenitor cells for support of high-dose cancer therapy. Blume K.G., Thomas E.D. Hematopoietic cell transplantation. 1999;Blackwell Scientific Publications, Malden, MA. 455p.
6. Klein HG, Price TH, Strauss RG, et al (1997) Granulocyte transfusion redux. Hematology 1997, Education Program American Society of Hematology, p. 138.
7. Auffermann S., Herzog R., Hebart H.et al. Granulocyte transfusions in neutropenic patients with life-threatening infections. Prophylactic and therapeutic use: Bone Marrow Transplant. 23(suppl. 1):1999;S110. (abstract).
8. Frenck R.W., Ventura G.J., Krannig G., Felix E.A., Zipf T.F., VanWinkle W.B., Buescher E.S. Studies of the function and structure of in vitro propagated human granulocytes. Pediatr Res. 30:1991;135.
9. Egeland T., Steen R., Quarsten H., Gaudernack G., Yang Y.C., Thorsby E. Myeloid differentiation of purified CD34+ cells after stimulation with recombinant human granulocyte-monocyte colony-stimulating factor (CSF), granulocyte-CSF, monocyte-CSF, and interleukin-3. Blood. 78:1991;3192.
10. Haylock D.N., To L.B., Dowse T.L., Juttner C.A., Simmons P.J. Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood. 80:1992;1405.
11. Smith S.L., Bender J.G., Maples P.B., Unverzagt K.L., Schilling M., Lum L., Williams S., Van E.D. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow. Exp Hematol. 21:1993;870.
12. Lill M.C., Lynch M., Fraser J.K., Chung G.Y., Schiller G., Glaspy J.A., Souza L., Baldwin G.C., Gasson J.C. Production of functional myeloid cells from CD34-selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system. Stem Cells. 12:1994;626.
13. Makino S., Haylock D.N., Dowse T., Trimboli S., Niutta S., To L.B., Juttner C.A., Simmons P.J. Ex vivo culture of peripheral blood CD34+ cells. effects of hematopoietic growth factors on production of neutrophilic precursors J Hematother. 6:1997;475.
14. Smith S.L., Bender J.G., Berger C., Lee W.J., Loudovaris M., Martinson J.A., Opotowsky J.D., Qiao X., Schneidkraut M., Sweeney P.et al. Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF). J Hematother. 6:1997;323.
15. Neildez-Nguyen T.M., Vetillard J., Drouet M., Herodin F., Brouard N., Mestries J.C., Thierry D. Functional studies of maturing myeloid cells during ex vivo expansion for treatment of aplasia. feasibility of ex vivo expansion from cryopreserved bone marrow cell samples J Hematother. 7:1998;69.
16. Brugger W., Heimfeld S., Berenson R.J., Mertelsmann R., Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med. 333:1995;283.
17. Brugger W., Mocklin W., Heimfeld S., Berenson R.J., Mertelsmann R., Kanz L. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood. 81:1993;2579.
18. Brugger W., Scheding S., Faul C.et al. Direct comparison of CD34+ selected vs. unselected peripheral blood progenitor cells (PBPC) for matched related allogeneic transplantation. Blood. 92:1998;112a. (abst).
19. Finke J., Brugger W., Bertz H., Behringer D., Kunzmann R., Weber N.R., Kanz L., Mertelsmann R. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Bone Marrow Transplant. 18:1996;1081.
20. Brugger W., Birken R., Bertz H., Hecht T., Pressler K., Frisch J., Schulz G., Mertelsmann R., Kanz L. Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. Br Haematol. 84:1993;402.
21. Bokemeyer C., Harstrick A., Beyer J., Metzner B., Ruther U., Hartmann J.T., Holstein K., Derigs H.G., de Wit R., Casper J.et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell, tumors. German Testicular Cancer Study Group. Semin Oncol. 25(2 suppl. 4):1998;24.
22. Brugger W., Fetscher S., Hasse J., Frommhold H., Presler K., Mertelsmann R., Engelhardt R., Kanz L. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. Semin Oncol. 25(1 suppl 2):1998;42.
23. Fetscher S., Brugger W., Bertz H., Krieger G., Kanz L., Mertelsmann R., Lange W. High-dose chemotherapy with autologous peripheral blood stem cell transplantation for metastatic gastric leiomyosarcoma. Bone Marrow Transplant. 20:1997;787.
24. Fetscher S., Brugger W., Engelhardt R., Kanz L., Hasse J., Frommhold H., Wenger M., Lange W., Mertelsmann R. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer. Ann Oncol. 8:1997;57.
25. Brugger W., Henschler R., Heimfeld S., Berenson R.J., Mertelsmann R., Kanz L. Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood. 84:1994;1321.
26. Rappold I., Ziegler B.L., Kohler I., Marchetto S., Rosnet O., Birnbaum D., Simmons P.J., Zannettino A.C., Hill B., Neu S.et al. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood. 90:1997;111.
27. + cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 5:1996;213.
28. Terstappen L.W., Safford M., Loken M.R. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia. 4:1990;657.
29. Reiffers J., Cailliot C., Dazey B., Attal M., Caraux J., Boiron J.M. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet. 354:1999;1092.
30. McNiece I., Jones R., Cagnoni P., Bearman S.I., Nieto Y., Shpall E.J. Ex-vivo expansion of hematopoietic progenitor cells. preliminary results in breast cancer Hematol Cell Ther. 41:1999;82.
31. McNiece I.K., Hami L., Jones R.et al. Transplantation of ex vivo expanded PBPC after high dose chemotherapy results in decreased neutropenia. Blood. 92:1998;126a. (abstr).
32. + cells in autologous stem cell transplantation for breast cancer. Blood. 87:1996;1687.
33. Martinson J.A., Loudovaris M., Smith S.L., Bender J.G., Vachula M., Van E.D., Kaizer H., Ghalie R.G., McLeod B.C. Ex vivo expansion of frozen/thawed CD34+ cells isolated from frozen human apheresis products. J Hematother. 6:1997;69.
34. Knapp W., Strobl H., Majdic O. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry. 18:1994;187.
35. Thomas J.W., Baum C.M., Hood W.F., Klein B., Monahan J.B., Paik K., Staten N., McKearn J.P. Potent interleukin 3 receptor agonist with selectively enhanced hematopoietic activity relative to recombinant human interleukin 3. Proc Natl Acad Sci USA. 92:1995;3799.
36. Lyman S.D. Biologic effects and potential clinical applications of Flt3 ligand. Curr Opin Hematol. 5:1998;192.
37. Unverzagt K.L., Bender J.G., Loudovaris M., Martinson J.A., Hazelton B., Weaver C. Characterization of a culture-derived CD15+CD11b-promyelocytic population from CD34+ peripheral blood cells. J Leuk Biol. 62:1997;480.
38. Scheding S., Franke H., Diehl V., Wichmann H.E., Brugger W., Kanz L., Schmitz S. How many myeloid post-progenitor cells have to be transplanted to completely abrogate neutropenia after high-dose chemotherapy and peripheral blood progenitor cell transplantation? Exp Hematol. 27:1999;956.
39. Stoney G.B., Briddell R.A., Kern B.P.et al. Clinical scale ex vivo expansion of myeloid progenitor cells and megakaryocytes under GMP conditions. Exp Hematol. 24:1996;1043. (abstr).